NCT02749695View on ClinicalTrials.gov

Efficiency of Placental Drug Melsmon® in Correction of Climacteric Symptoms in Premenopausal Women

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2014

Conditions
Climacteric Syndrome
Interventions
DRUG

Melsmon

Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).

OTHER

Placebo

2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).

Trial Locations (1)

664003

Scientific Center for Family Health and Human Reproduction Problems, Russia, Irkutsk

All Listed Sponsors
lead

Inna I. Kovalenko

OTHER_GOV

NCT02749695 - Efficiency of Placental Drug Melsmon® in Correction of Climacteric Symptoms in Premenopausal Women | Biotech Hunter | Biotech Hunter